Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Phase 3positiveTam-PelitopotecanPositive
AI Analysis
Summary
Roche's collaborator MediLink announced positive Phase 3 TAISHAN-302 trial results for Tam-Peli in Chinese patients with relapsed small-cell lung cancer, demonstrating statistically significant overall survival benefit with 54% reduction in death risk versus topotecan. The drug met its primary endpoint and showed robust improvements across secondary efficacy endpoints.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met primary endpoint of overall survival with 54% reduction in risk of death (median OS 13.3 vs. 9.4 months, HR=0.46, p<0.0001). Secondary endpoints also met: PFS 7.4 vs. 2.8 months; response rates 59.1% vs. 9.7%.
Importance:8/10
Sentiment:
0.90
Phase 3 DataOncologySmall-Cell Lung CancerChinaPositive ResultsOverall Survival Benefit
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 13, 2026 12:00 AM